<DOC>
	<DOCNO>NCT00376090</DOCNO>
	<brief_summary>The purpose study determine safety immune response HIV vaccine candidate , MVA-CMDR . This vaccine design induce immune response three HIV `` passenger '' gene encode viral vector , MVA .</brief_summary>
	<brief_title>Safety Immune Response Modified Vaccinia Ankara ( MVA ) HIV Vaccine HIV Uninfected Adults</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>A participant must meet following criterion : Low risk HIV infection 18 40 year time enrollment vaccinia naive Good health Availability 12 month participation . Successful completion Test Understanding Able willing give inform consent . HEMATOCRIT : WOMEN : 35 % 45 % ; MEN 36 % 49 % White cell count : 3,000 11,000 cells/mm3 Platelets : 125,000 450,000 per mm3 Normal cardiac enzyme level second Screening Visit Urinalysis ( UA ) protein blood : negative trace . Normal liver function test include ALT/AST , alkaline phosphatase , GGT ( &lt; 1.25x institutional upper limit normal ) CPK ( &lt; 480 ) creatinine ( &lt; 1.25 mg/dL ) Negative serology HIV infection Any female volunteer must negative serum urine pregnancy test screen visit well immediately prior vaccine/placebo vaccination , well verbal assurance adequate birth control measure follow 60 day prior first vaccine/placebo vaccination continue follow least 3months final vaccine/placebo vaccination . This mean use follow method : Birth control drug prevent pregnancy give pill , shot place skin , Male female condom without cream gel kill sperm , diaphragm cervical cap cream gel kill sperm , Abstinence A volunteer exclude one follow condition apply . A woman : Is pregnant . Is breastfeed . Anyone : Is U.S. military personnel . Acknowledges engage highestrisk behavior within six month study entry Has active tuberculosis systemic infectious process review system physical examination . Has history know cardiac disease include following : prior myocardial infarction ( heart attack ) , angina pectoris , congestive heart failure , conduction disturbance , repolarization ( ST segment T wave ) abnormality , serious cardiac arrhythmia ( ventricular tachycardia ventricular fibrillation ) , cardiomyopathy , pericarditis , stroke transient ischemic attack , chest pain shortness breath activity ( e.g . climb stair ) , valvular heart disease include mitral valve prolapse , heart condition care doctor . Has ECG Screening Visit 2 clinical significant finding , feature would interfere assessment myo/pericarditis ( determine contract ECG Lab ) include follow : conduction disturbance ( atrioventricular intraventricular condition , leave right bundle branch block , AB block degree QTc prolongation ) , repolarization ( ST segment T wave ) abnormality , significant atrial ventricular arrhythmia , frequent atrial ventricular ectopy ( e.g . frequent premature atrial contraction , 2 premature ventricular contraction row ) , ST elevation consistent ischemia , evidence past evolve myocardial infarction Has history seizure disorder , immunodeficiency , chronic illness , autoimmune disease , diabetes mellitus active malignancy use immunosuppressive medication . Has evidence psychiatric , medical and/or substance abuse problem past six month investigator believe would adversely affect volunteer 's ability participate trial . Has occupational responsibility would prevent completion participation study . Has receive live attenuate vaccine within 60 day study entry . Has use experimental therapeutic agent within 30 day study entry . Has receive blood product immunoglobulins past three month . Has history anaphylaxis serious adverse reaction vaccine . Has previously receive HIV vaccine MVA vaccinia vaccine . Has chronic active Hepatitis B Hepatitis C virus infection active syphilis ( positive RPR FTA ) . Has immediate type hypersensitivity reaction egg , egg product neomycin/streptomycin ( use prepare MVA vaccine ) . Is study site employee .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>MVA vector</keyword>
	<keyword>Immunogenicity</keyword>
	<keyword>HIV vaccine</keyword>
	<keyword>HIV preventative vaccine</keyword>
</DOC>